**Author details**

Marwa Zakaria\* and Tamer Hassan Faculty of Medicine, Zagazig University, Zagazig, Egypt

\*Address all correspondence to: marwazakaria12@yahoo.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**9**

*Introductory Chapter: β-Thalassemia*

[1] Rund D, Rachmilewitz E. Betathalassemia. The New England Journal of Medicine. 2005;**353**:1135-1146. DOI:

10.1056/NEJMra050436

[2] Kan YW, Nathan DG. Mild

[3] Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematology/Oncology Clinics of North America. 2014;**28**:683-701. DOI: 10.1016/j.hoc.2014.04.003

[4] Rombout-Sestrienkova E, van Kraaij MG, Koek GH. How we manage patients with hereditary haemochromatosis. British Journal of Haematology. 2016;**175**:759-770. DOI:

10.1111/bjh.14376

[5] Leitch HA, Fibach E,

critrevonc.2017.03.002

Rachmilewitz E. Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. Critical Reviews in Oncology/Hematology. 2017;**113**:156-170. DOI: 10.1016/j.

[6] Haghpanah S, Zarei T, Zahedi Z, et al. Compliance and satisfaction with Deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology. 2014;**19**:187-191. DOI: 10.1179/1607845413Y.0000000121

[7] Chuansumrit A, Songdej D, Sirachainan N, et al. Safety profile

of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: A 1-year experience. Paediatrics and International Child

thalassemia: The result of interactions of alpha and beta thalassemia genes. The Journal of Clinical Investigation. 1970;**49**:635-642. DOI: 10.1172/

**References**

JCI106274

*DOI: http://dx.doi.org/10.5772/intechopen.90946*

Health. 2016;**36**:209-213. DOI: 10.1179/2046905515Y.0000000040

10.1002/ajh.24668

10.1111/bjh.13512

intracellular iron chelation combinations: Mechanisms and conditions for optimizing iron mobilization. British Journal of Haematology. 2015;**170**:874-883. DOI:

[8] Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of Deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. American Journal of Hematology. 2017;**92**:420-428. DOI:

[9] Vlachodimitropoulou Koumoutsea E, Garbowski M, Porter J. Synergistic

[10] Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nature Medicine. 2014;**20**:398-407. DOI: 10.1038/nm.3468

Cappellini MD. Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opinion on Investigational Drugs. 2017;**26**:793-802. DOI: 10.1080/13543784.2017.1335709

[12] Casu C, Oikonomidou PR, Lo Presti V, et al. Potential therapeutic applications of JAK2 inhibitors and HIF2a-ASO for the treatment of betathalassemia intermedia and major. American Journal of Hematology. 2017;**92**:E221-E221. DOI: 10.3324/

[13] Guillem F, Dussiot M, Causse S, et al. XPO1 (exportin-1) is a major regulator of human erythroid differentiation. Potential clinical applications to decrease ineffective erythropoiesis of beta-thalassemia.

Blood. 2015;**126**:2368. DOI: 10.1155/2013/394295

haematol.2017.181511

[11] Motta I, Scaramellini N,

*Introductory Chapter: β-Thalassemia DOI: http://dx.doi.org/10.5772/intechopen.90946*
